Form 4: ESSA Pharma CFO Sells Shares Post-Merger

ESSA Pharma Inc.'s Chief Financial Officer, David S. Wood, reported the disposal of 33,343 common shares following a business combination.

Summary

• David S. Wood, Chief Financial Officer of ESSA Pharma Inc., disposed of 33,343 common shares.
• The transaction occurred on October 9, 2025, as a result of a business combination.
• The business combination involved XenoTherapeutics, Inc., Xeno Acquisition Corp. (Purchaser), and XOMA Royalty Corporation acquiring all outstanding common shares of ESSA Pharma Inc.
• Shareholders received approximately US$0.12 in cash per share and one contingent value right (CVR) per share, potentially worth up to US$0.14 per CVR.
• Following this transaction, David S. Wood beneficially owns 0 common shares of ESSA Pharma Inc.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a standard insider report following a merger, indicating the completion of a corporate event. The consideration includes both cash and CVRs, offering some potential upside for former shareholders.

Stakeholder Impact

• Shareholders of ESSA Pharma Inc. received cash and CVRs as consideration for their shares, indicating the completion of the company's acquisition.
• The reporting person, as a former shareholder and officer, no longer holds direct beneficial ownership in ESSA Pharma Inc. common shares.

Key Dates

Keywords

ESSA Pharma, EPIX, Form 4, Insider Transaction, David S. Wood, CFO, Business Combination, Merger, Share Disposal, Contingent Value Right, XenoTherapeutics, XOMA Royalty